
Biographie pas encore disponible.
Publications
2024
Nifuroxazide rescues the deleterious effects due to CHCHD10 -associated MICOS defects in disease models,
Brain - A Journal of Neurology , 2024, Online ahead of print. ⟨10.1093/brain/awae348⟩.
2024
Bio-inspired synthesis and profiling of a potent antiviral flavonol targeting the lipid exchanger OSBP,
2024.
2023
A double-spiral maze and hi-resolution tracking pipeline to study dispersal by groups of minute insects,
Scientific Reports, 2023, 13 (1), pp.5200. ⟨10.1038/s41598-023-31630-8⟩.
2023
When complex movement yields simple dispersal: behavioural heterogeneity, spatial spread and parasitism in groups of micro-wasps,
Movement Ecology, 2023, 11 (1), pp.13. ⟨10.1186/s40462-023-00371-8⟩.
2023
Migration pulsedness alters patterns of allele fixation and local adaptation in a mainland-island model,
Evolution - International Journal of Organic Evolution, 2023, 77 (3), pp.718-730. ⟨10.1093/evolut/qpac067⟩.
2022
Cdk5-p25 as a key element linking amyloid and tau pathologies in Alzheimer’s disease: Mechanisms and possible therapeutic interventions.,
Life Sci 2022 Nov; 308(): 120986.
2022
ADAM10 pharmacological inhibition modifies the expression of components of the dopaminergic system,
2023.
2022
Low T Cell Responsiveness in the Early Phase of COVID-19 Associates with Progression to Severe Pneumonia in Kidney Transplant Recipients,
Viruses, 2022, 14 (3), pp.542. ⟨10.3390/v14030542⟩.
2022
DHA-containing phospholipids control membrane fusion and transcellular tunnel dynamics,
Journal of Cell Science, 2022, 135 (5), pp.jcs259119. ⟨10.1242/jcs.259119⟩.
2021
A standardised hERG phenotyping pipeline to evaluate KCNH2 genetic variant pathogenicity,
Clinical and Translational Medicine, 2021, 11 (11), ⟨10.1002/ctm2.609⟩.
2021
A comprehensive library of fluorescent constructs of SARS‐CoV‐2 proteins and their initial characterisation in different cell types,
Biology of the Cell, 2021, 113 (7), pp.311-328. ⟨10.1111/boc.202000158⟩.
2021
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition),
Autophagy, 2021, 17 (1), pp.1-382. ⟨10.1080/15548627.2020.1797280⟩.
2019
Anti-PLA2R1 Antibodies Containing Sera Induce In Vitro Cytotoxicity Mediated by Complement Activation,
Journal of Immunology Research, 2019, 2019, pp.1-14. ⟨10.1155/2019/1324804⟩.
2019
Involvement of Phosphodiesterase 2A Activity in the Pathophysiology of Fragile X Syndrome,
Cerebral Cortex, 2019, 29 (8), pp.3241-3252. ⟨10.1093/cercor/bhy192⟩.
2019
The OncoAge Consortium: Linking Aging and Oncology from Bench to Bedside and Back Again,
Cancers, 2019, 11 (2), pp.1-11. ⟨10.3390/cancers11020250⟩.
2017
Eμ and 3’RR IgH enhancers show hierarchic unilateral dependence in mature B-cells,
Scientific Reports, 2017, 7 (1), pp.442. ⟨10.1038/s41598-017-00575-0⟩.
2017
The Polyherbal Wattana Formula Displays Anti-Amyloidogenic Properties by Increasing α-Secretase Activities.,
PLoS One 2017 ; 12(1): e0170360.
2016
Deciphering the importance of the palindromic architecture of the immunoglobulin heavy-chain 3’ regulatory region,
Nature Communications, 2016, 7, pp.10730. ⟨10.1038/ncomms10730⟩.
2013
Multicenter quality control of hepatitis C virus protease inhibitor resistance genotyping.,
Journal of Clinical Microbiology, 2013, 51 (5), pp.1428-33. ⟨10.1128/JCM.03032-12⟩.
2013
Further characterization of a putative serine protease contributing to the γ-secretase cleavage of β-amyloid precursor protein,
Bioorganic and Medicinal Chemistry Letters, 2013, 21 (4), pp.1018-1029. ⟨10.1016/j.bmc.2012.11.045⟩.
2011
A metabolomic and systems biology perspective on the brain of the fragile X syndrome mouse model.,
Genome Research, 2011, 21 (12), pp.2190-202. ⟨10.1101/gr.116764.110⟩.
2011
The extracellular regulated kinase-1 (ERK1) controls regulated alpha-secretase-mediated processing, promoter transactivation, and mRNA levels of the cellular prion protein.,
J Biol Chem 2011 Aug; 286(33): 29192-29206.
2010
Task2 potassium channels set central respiratory CO 2 and O 2 sensitivity,
Proceedings of the National Academy of Sciences of the United States of America, 2010, 107 (5), pp.2325-2330. ⟨10.1073/pnas.0910059107⟩.
2008
Kinetic analysis of the regulation of the Na+/H+ exchanger NHE-1 by osmotic shocks.,
Biochemistry, 2008, 47 (51), pp.13674-85. ⟨10.1021/bi801368n⟩.
2007
Les récepteurs muscariniques M1 et M3 induisent le métabolisme physiologique de la PrPc et de la ßAPP en modulant la phosphorylation et l’activité d’ADAM 17,
9ème Réunion francophone sur la maladie d'Alzheimer et les syndromes apparentés, Nov 2007, Nice, France.
2007
The gamma/epsilon-secretase-derived APP intracellular domain fragments regulate p53.,
Curr Alzheimer Res 2007 Sep; 4(4): 423-6.
2007
M1 and M3 muscarinic receptors control physiological processing of cellular prion by modulating ADAM17 phosphorylation and activity.,
Journal of Neuroscience, 2007, 27 (15), pp.4083-92. ⟨10.1523/JNEUROSCI.5293-06.2007⟩.
2007
Response to correspondence: Pardossi-Piquard et al., « Presenilin-dependent transcriptional control of the Abeta-degrading enzyme neprilysin by intracellular domains of betAAPP and APLP. » Neuron 46, 541-554.,
Neuron 2007 Feb; 53(4): 483-6.
2006
Presenilin-dependent gamma-secretase-mediated control of p53-associated cell death in Alzheimer’s disease.,
J Neurosci 2006 Jun; 26(23): 6377-85.
2006
Development and characterization of nanocomposite materials,
Nanostructured and functional polymer-based materials and composites, May 2006, Lyon, France.
2005
Presenilin-dependent transcriptional control of the Ab-degrading enzyme neprilysin by intracellular domains of bAPP and APLP,
Neuron, 2005, 46, pp.551-554.
2004
Primary cultured neurons devoid of cellular prion display lower responsiveness to staurosporine through the control of p53 at both transcriptional and post-transcriptional levels.,
Journal of Biological Chemistry, 2004, 279, pp.612-618.
2001
Endogenous beta-amyloid production in presenilin-deficient embryonic mouse fibroblasts.,
Nat Cell Biol 2001 Nov; 3(11): 1030-3.
1997
Effect of a novel selective and potent phosphinic peptide inhibitor of endopeptidase 3.4.24.16 on neurotensin-induced analgesia and neuronal inactivation.,
Br J Pharmacol 1997 Jun; 121(4): 705-10.
1996
Purification and characterization of human endopeptidase 3.4.24.16. Comparison with the porcine counterpart indicates a unique cleavage site on neurotensin.,
Brain Res 1996 Feb; 709(1): 51-8.
1993
Recent advances on endopeptidase-3.4.24.16.,
Biochem Soc Trans 1993 Aug; 21 ( Pt 3)(3): 692-7.
1993
Differential catabolic fate of neuromedin N and neurotensin in the canine intestinal mucosa.,
Peptides 1993 ; 14(3): 457-63.